Citius Pharmaceuticals (NASDAQ:CTXR) Raised to Buy at D. Boral Capital

D. Boral Capital upgraded shares of Citius Pharmaceuticals (NASDAQ:CTXR) from a hold rating to a buy rating in a research note released on Monday morning, MarketBeat.com reports. D. Boral Capital currently has $9.00 price objective on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $100.00 price target on shares of Citius Pharmaceuticals in a report on Tuesday, November 12th.

Citius Pharmaceuticals Trading Up 2.3 %

Shares of NASDAQ CTXR opened at $4.00 on Monday. The firm’s 50-day moving average price is $5.43 and its 200-day moving average price is $11.89. The firm has a market capitalization of $30.91 million, a P/E ratio of -0.67 and a beta of 1.48. Citius Pharmaceuticals has a 1-year low of $2.44 and a 1-year high of $26.75.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Point72 DIFC Ltd acquired a new stake in shares of Citius Pharmaceuticals in the 2nd quarter worth about $29,000. XTX Topco Ltd bought a new stake in Citius Pharmaceuticals during the 3rd quarter worth approximately $47,000. Miller Investment Management LP raised its stake in shares of Citius Pharmaceuticals by 99.3% in the third quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock worth $50,000 after purchasing an additional 49,640 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Citius Pharmaceuticals in the third quarter valued at approximately $50,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Citius Pharmaceuticals during the second quarter valued at approximately $69,000. 16.88% of the stock is owned by institutional investors.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.